Trials / Withdrawn
WithdrawnNCT04588441
The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19
Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19 (The ARCTIC Trial)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Florida · Academic / Other
- Sex
- All
- Age
- 18 Years – 105 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II study to test adenosine efficacy for down-regulation of the overwhelming inflammation of COVID-19 in the lungs as reflected by clinical recovery of lung function; resolution of clinically relevant markers of lung function, and resolution of systemic markers of inflammation and coagulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adenosine | Adenosine will be given like an inhaled asthma medication two times daily for one week (7 days). Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer. |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2020-10-19
- Last updated
- 2024-05-06
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04588441. Inclusion in this directory is not an endorsement.